The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2025 | The future of Nous-209 vaccination in preventing Lynch syndrome
Jason Willis, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes on the potential of Nous-209 vaccination in reducing the burden of adenomas, a precursor to colon cancer. A larger, randomized study is needed to confirm the hypothesis that simulating an immune response against frameshift peptides leads to a decrease in adenoma burden. This study aims to compare Nous-209 vaccination to no intervention or standard care with aspirin or naproxen, with the goal of determining whether vaccination leads to a reduction in adenoma burden over time. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
